PDF(Sci-hub)
Abstract：
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an emerging and indolent, but potentially fatal cancer of the immune system that can develop around textured-surface breast implants. The World Health Organization first recognized BIA-ALCL as a unique clinical entity in 2016. To date, over 600 confirmed cases have been reported worldwide. BIA-ALCL most commonly presents with disease confined to the capsule, as a seroma or a mass adjacent to the implant. While BIA-ALCL has a fairly indolent clinical course, with an excellent prognosis in early stage disease, disseminated cancer and death have also been reported. In this review, the authors focus on the early diagnosis and treatment, including reconstructing the breast following BIA-ALCL, and also discuss recently updated National Comprehensive Cancer Network guidelines. They also review the current epidemiology and risk factors associated with BIA-ALCL. Finally, they discuss important medicolegal considerations and the bioethics surrounding the continued use of textured-surface breast implants.
摘要：
乳房植入物相关的间变性大细胞淋巴瘤（BIA-ALCL）是一种新兴的，而是可能致命的免疫系统癌症，可以在纹理表面的乳房植入物周围发展。世界卫生组织于2016年首次将BIA-ALCL认定为独特的临床实体。迄今为止,全球已报告600多例确诊病例。BIA-ALCL通常表现为局限于胶囊的疾病，作为植入物附近的血清肿或肿块。虽然BIA-ALCL的临床过程相当缓慢，早期疾病预后良好，播散性癌症和死亡也有报道。在这次审查中,作者专注于早期诊断和治疗，包括BIA-ALCL后的乳房重建，并讨论最近更新的国家综合癌症网络指南。他们还回顾了目前与BIA-ALCL相关的流行病学和危险因素。最后,他们讨论了重要的法医学考虑因素以及围绕继续使用纹理表面乳房植入物的生物伦理学。
